Gene-editing alternative corrects Duchenne muscular dystrophy
UT Southwestern Medical Center May 10, 2017
Using the new gene–editing enzyme CRISPR–Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.
The UT Southwestern group had previously used CRISPR–Cas9, the original gene–editing system, to correct the Duchenne defect in a mouse model of the disease and in human cells. In the current work, they used a new variation of the gene–editing system to repair the defect in both a mouse model and in human cells.
ÂWe took patient–derived cells that had the most common mutation responsible for Duchenne muscular dystrophy and we corrected them in vitro to restore production of the missing dystrophin protein in the cells. This work provides us with a promising new tool in the CRISPR toolbox, said author Dr. Eric Olson, Chairman of Molecular Biology, Co–Director of the UT Southwestern Wellstone Muscular Dystrophy Cooperative Research Center, and Director of the Hamon Center for Regenerative Science and Medicine.
The research appeared in the journal Science Advances.
CRISPR–Cpf1 differs from CRISPR–Cas9 in a number of key ways. Cpf1 is much smaller than the Cas9 enzyme, which makes it easier to package inside a virus and therefore easier to deliver to muscle cells.
It also recognizes a different sequence of DNA than Cas9 does, which provides greater flexibility in terms of use. ÂThere will be some genes that may be difficult to edit with Cas9 but may be easier to modify with Cpf1, or vice versa. The two proteins have different biochemical properties and recognize different DNA sequences, so these properties create more options for gene–editing, said Dr. Olson, who holds the Pogue Distinguished Chair in Research on Cardiac Birth Defects, the Robert A. Welch Distinguished Chair in Science, and the Annie and Willie Nelson Professorship in Stem Cell Research.
ÂBy either skipping a mutation region or precisely repairing a mutation in the gene, CRISPR–Cpf1–mediated genome editing not only corrects Duchenne muscular dystrophy mutations but also improves muscle contractility and strength, said co–author Dr. Rhonda Bassel–Duby, Professor of Molecular Biology and Associate Director of the Hamon Center for Regenerative Science and Medicine.
Go to Original
The UT Southwestern group had previously used CRISPR–Cas9, the original gene–editing system, to correct the Duchenne defect in a mouse model of the disease and in human cells. In the current work, they used a new variation of the gene–editing system to repair the defect in both a mouse model and in human cells.
ÂWe took patient–derived cells that had the most common mutation responsible for Duchenne muscular dystrophy and we corrected them in vitro to restore production of the missing dystrophin protein in the cells. This work provides us with a promising new tool in the CRISPR toolbox, said author Dr. Eric Olson, Chairman of Molecular Biology, Co–Director of the UT Southwestern Wellstone Muscular Dystrophy Cooperative Research Center, and Director of the Hamon Center for Regenerative Science and Medicine.
The research appeared in the journal Science Advances.
CRISPR–Cpf1 differs from CRISPR–Cas9 in a number of key ways. Cpf1 is much smaller than the Cas9 enzyme, which makes it easier to package inside a virus and therefore easier to deliver to muscle cells.
It also recognizes a different sequence of DNA than Cas9 does, which provides greater flexibility in terms of use. ÂThere will be some genes that may be difficult to edit with Cas9 but may be easier to modify with Cpf1, or vice versa. The two proteins have different biochemical properties and recognize different DNA sequences, so these properties create more options for gene–editing, said Dr. Olson, who holds the Pogue Distinguished Chair in Research on Cardiac Birth Defects, the Robert A. Welch Distinguished Chair in Science, and the Annie and Willie Nelson Professorship in Stem Cell Research.
ÂBy either skipping a mutation region or precisely repairing a mutation in the gene, CRISPR–Cpf1–mediated genome editing not only corrects Duchenne muscular dystrophy mutations but also improves muscle contractility and strength, said co–author Dr. Rhonda Bassel–Duby, Professor of Molecular Biology and Associate Director of the Hamon Center for Regenerative Science and Medicine.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries